COVID-19 alternating dose vaccine study launches in UK
Patients taking part in a new clinical study will soon receive different COVID-19 vaccines for their first or second dose.
Backed by £7 million of Government funding, the study will be the first in the world to determine the effects of using different vaccines for the first and second dose – for example, using Oxford University/AstraZeneca’s vaccine for the first dose, followed by Pfizer/BioNTech’s vaccine for the second.
The study, run by the National Immunisation Schedule Evaluation Consortium (NISEC) across 8 National Institute for Health Research (NIHR) supported sites, will also gather immunological evidence on different intervals between the first and second dose for a mixed-vaccine regimen against control groups when the same vaccine is used for both doses.
A same-dose regimen is currently implemented for the national COVID-19 vaccination programme, and there are no current plans for this to change. Anyone who has received either the Pfizer or AstraZeneca vaccination as part of the UK-wide delivery plan will not be affected by this study. They will receive their second dose from the same source and over the same 12-week interval.
The 13-month study will monitor the impact of the different dosing regimens on patients’ immune responses, which have the potential to be higher or lower than from the same dose regimen. Initial findings are expected to be released in the summer. The study has received ethics approval from the Research Ethics Committee, as well as approval from the Medicines and Healthcare products Regulatory Agency (MHRA).
Should the study show promising results, then the government may consider reviewing the vaccine regimen approach if needed, but only if proven to be safe and recommended by the Joint Committee on Vaccination and Immunisation (JCVI).
Minister for COVID-19 Vaccine Deployment, Nadhim Zahawi, said: "This is a hugely important clinical trial that will provide us with more vital evidence on the safety of these vaccines when used in different ways.
"Nothing will be approved for use more widely than the study, or as part of our vaccine deployment programme, until researchers and the regulator are absolutely confident the approach is safe and effective. This is another great step forwards for British science, expertise and innovation, backed by government funding – and I look forward to seeing what it produces."
Deputy Chief Medical Officer and Senior Responsible Officer for the study, Professor Jonathan Van-Tam, said: "Given the inevitable challenges of immunising large numbers of the population against COVID-19 and potential global supply constraints, there are definite advantages to having data that could support a more flexible immunisation programme, if needed. It is also even possible that by combining vaccines, the immune response could be enhanced giving even higher antibody levels that last longer; unless this is evaluated in a clinical trial we just won’t know. This study will give us greater insight into how we can use vaccines to stay on top of this nasty disease."
The study will initially have 8 different arms testing 8 different combinations, but more products may be added. The 8 arms include:
- 2 doses of the Oxford/AstraZeneca vaccine at 28 days apart
- 2 doses of the Oxford/AstraZeneca vaccine at 12 weeks apart – as a control group
- 2 doses of the Pfizer/BioNTech vaccine at 28 days apart
- 2 doses of the Pfizer/BioNTech vaccine at 12 weeks apart – as a control group
- the Oxford/AstraZeneca vaccine for the first dose, followed by the Pfizer/BioNTech vaccine for the second, at 28 days apart
- the Oxford/AstraZeneca vaccine for the first dose, followed by the Pfizer/BioNTech vaccine for the second, at 12 weeks apart
- the Pfizer/BioNTech vaccine for the first dose, followed by the Oxford/AstraZeneca vaccine for the second, at 28 days apart
- the Pfizer/BioNTech vaccine for the first dose, followed by the Oxford/AstraZeneca vaccine for the second, at 12 weeks apart
Over 800 patients are expected to take part in the study, referred to as the COVID-19 Heterologous Prime Boost study or ‘Com-Cov’, across 8 different sites across England – including in London, Birmingham and Liverpool.
Patients will be recruited over the course of February via the NHS COVID-19 Vaccine Research Registry, with vaccinations expected to start towards the middle of the month and initial results to be made available over the summer period. The UK public can volunteer to be contacted about taking part in the study and further vaccine studies by joining the registry.
We are the foremost auctioneers and asset managers to the health sector and the leading medical equipment resellers in Europe. Founded over 25 years ago, we actively created a market for used medical equipment and convinced hospitals to sell assets, developing processes specific to the health sector.